Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects

Inclusion Criteria: * Body mass index must be between 18.0 kg/m2 and ≤ 31.5 kg/m2; * Non-smokers for at least 3 months preceding screening; * Females subjects must be of non-childbearing potential e.g., post-menopausal or pre-menopausal with surgical sterilization; * Males agree to use appropriate contraception; * Medical history must be verified by either a personal physician or medical practitioner as appropriate; * Willing to give written informed consent and are willing to comply with the study requirements. Exclusion Criteria: * Known hepatitis B surface antigen (HBsAg), hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection * Multiple drug allergies or know sensitivity to oligonucleotide * History of drug abuse and/or alcohol abuse * Receiving an investigational agent within 3 months prior to study drug administration * Subjects with safety laboratory test results deemed clinical significant by the Investigator; * Received prescription drugs within 4 weeks of first dosing * Subjects who have donated more than 500 mL of blood within the 3 months prior to ALN-PCS02 or placebo administration; * Subjects who have used prescription drugs within 4 weeks of first dosing * Considered unfit for the study by the Principal Investigator * Employee or family member of the sponsor or the clinical study site personnel